Last reviewed · How we verify
NCT05931146
Effectiveness of Smartphone Application for Weight Loss
NA trial testing MyNetDiary app group in Weight Loss in 20 participants. Completed in 15 August 2023.
31 July 2023
Quick facts
| Lead sponsor | Riphah International University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 1 March 2023 |
| Primary completion | 31 July 2023 |
| Estimated completion | 15 August 2023 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- MyNetDiary app group
- Paper diary group
Conditions studied
- Weight Loss — all drugs for Weight Loss →
Sponsor
Riphah International University
Who can join
Adults 18 to 40, female only, with Weight Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is To determine the effectiveness of smartphone application for weight loss in healthy female adults. To determine the association between fitness application usage and physical activity behavior of the healthy female adults.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mobile health (m-health) smartphone interventions for adolescents and adults with overweight or obesity.
Metzendorf MI, Wieland LS, Richter B. · · 2024 · cited 28× · PMID 38375882 · DOI 10.1002/14651858.cd013591.pub2
Verify or expand the search:
- PubMed search for NCT05931146
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Weight Loss
Currently open trials in the same condition.
- NCT06811324 — Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults · Phase 2 · recruiting
- NCT07223983 — Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) · Phase 1 · recruiting
- NCT07213466 — Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder · Phase 4 · recruiting
- NCT06785064 — Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance · NA · recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other Riphah International University trials
Trials by the same sponsor.
- NCT07579585 — Effects of Photobiomodulation in Hemophilia Patients. · NA · recruiting
- NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
- NCT07484477 — Sedentary Behavior Modification, Cardiopulmonary Function & QOL Post Cardiac Surgery Patients. · NA · not yet recruiting
- NCT07438587 — Comparative Effects of Cadence Training vs Elliptical Training in Cricketers · NA · not yet recruiting
- NCT07484399 — Comparing Effects of HIIT and MICT on Functional Mobility, Muscle Strength, and Quality of Life in Diabetic Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05931146 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Riphah International University
- Last refreshed: 5 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05931146.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing